Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintained a $17 price target.
May 18, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides reiterated an Outperform rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintained a $17 price target.
The reiteration of the Outperform rating and maintenance of the $17 price target by Wedbush analyst Andreas Argyrides indicates a positive outlook for ARS Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100